CLAIMS

1. (currently amended) A compound of Formula ~~I(i) or I(j):~~



~~I(i) or~~



~~I(j)~~



or



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is C_6-C_{10} aryl substituted with 0-3 R^{1a}, or a C_3-C_8 cycloalkyl substituted with 0-2 R^{1b}, wherein said C_3-C_8 cycloalkyl is saturated or unsaturated;

each R^{1a} is independently a member selected from the group consisting of H, C_1-C_3 perfluoroalkyl, C_3-C_7 cycloalkyl, F, Cl, Br, CN, NO_2, OR^{10}, SCH_3, $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{11}R^{12}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, phenyl substituted with 0-3 R^{15}, and a C_1-C_4 alkyl substituted with 0-2 R^{16};

each R^{1b} is independently a member selected from the group consisting of H, OH, F, Cl, acetyl, =O, C_1-C_6 alkyl, C_1-C_6 alkoxy, CF_3 and OCF_3;

R^2 is a member selected from the group consisting of a phenyl substituted with 0-3 R^{15}, a C_1-C_6 alkyl substituted with 0-2 R^{2a}, a C_2-C_6 alkenyl, a C_2-C_6 alkynyl, a C_3-C_7 cycloalkyl substituted with 0-2 R^{19}, and a C_7-C_{11} bicycloalkyl substituted with 0-2 R^{19};

each R^{2a} is independently a member selected from the group consisting of a C_6-C_{10} aryl substituted with 0-3 R^{15}, a C_3-C_8 cycloalkyl substituted with 0-2 R^{19}, and a C_7-C_{11} bicycloalkyl substituted with 0-2 R^{19};

~~R^3 is a member selected from the group consisting of H and C_1-C_4 alkyl;~~

R^5 is a member selected from the group consisting of H, C_3-C_7 cycloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkyne, phenyl substituted with 0-2 R^{15}; and a C_1-C_6 alkyl substituted with 0-2 R^{18};

~~each of R^6, R^7, and R^8 is independently a member selected from the group consisting of H and C_1-C_4 alkyl;~~

each R^{10} is independently a member selected from the group consisting of H, C_3-C_7 cycloalkyl, a C_1-C_3 perfluoroalkyl, a C_1-C_4 alkyl substituted with 0-1 R^{25}, and a phenyl substituted with 0-3 R^{15};

each R^{11} is independently a member selected from the group consisting of H, ^{t}BOC, Cbz, C_3-C_8 cycloalkyl, (C_1-C_6 alkyl)-C(=O)-, (C_1-C_6 alkyl)-S(=O)$_2$- and a C_1-C_6 alkyl;

each of R^{12}, R^{13} and R^{14} is independently a member selected from the group consisting of H and C_1-C_4 alkyl;

each R^{15} is independently a member selected from the group consisting of H, OH, F, Cl, Br, I, CN, NO_2, $COOR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, acetyl, $-SCH_3$, $-S(=O)CH_3$, $-S(=O)_2CH_3$, $NR^{26}R^{27}$, C_1-C_6 alkoxy, C_1-C_3 perfluoroalkyl, C_1-C_3 perfluoroalkoxy and a C_1-C_6 alkyl;

each R^{16} is independently a member selected from the group consisting of H, OH, $COOR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, acetyl, $-SCH_3$, $-S(=O)CH_3$, $-S(=O)_2CH_3$, C_1-C_6 alkoxy, $NR^{26}R^{27}$, and a phenyl substituted with 0-3 R^{15};

each R^{18} is independently a member selected from the group consisting of H, OH, F, Cl, CN, NO_2, $C(=O)OR^{30}$, $C(=O)NR^{13}R^{14}$, $NR^{11}R^{12}$, a C_1-C_3 perfluoroalkyl, a C_1-C_3 perfluoroalkoxy, a phenyl substituted with 0-3 R^{15}; and C_3-C_8 cycloalkyl;

each R^{19} is independently a member selected from the group consisting of C_1-C_4 alkyl, F, Cl, C_1-C_4 alkoxy, CF_3 and OCF_3;

R^{23} is a bond, H, F, OH, C_1-C_4 alkyl, and C_1-C_3 alkylhydroxy;

each R^{25} is independently a member selected from the group consisting of H, C_3-C_7 cycloalkyl, and a phenyl substituted with 0-3 R^{15};

each R^{26} is independently a member selected from the group consisting of H, C_1-C_4 alkyl, (C_1-C_4 alkyl)-C(=O)- and (C_1-C_4 alkyl)-S(=O)$_2$-;

each R^{27} is independently a member selected from the group consisting of H and C_1-C_4 alkyl;

each R^{28} is independently a member selected from the group consisting of H, a C_1-C_6 alkyl, C_3-C_8 cycloalkyl, a phenyl substituted with 0-3 R^{15}, and a benzyl substituted with 0-2 R^{15};

each R^{29} is independently a member selected from the group consisting of H, F, Cl, Br, I, CN, NO_2, OR^{28}, SR^{28}, $S(=O)R^{28}$, $S(=O)_2R^{28}$, $S(=O)_2NR^{13}R^{14}$, $NR^{26}R^{27}$, acetyl, $C(=O)NR^{13}R^{14}$, $C(=O)OR^{13}$, C_1-C_6 alkyl, $OCHF_2$, SCF_3, OCF_3, and $-C(=NH)NH_2$; and

each R^{30} is independently a member selected from the group consisting of H, C_3-C_7 cycloalkyl, C_1-C_4 alkyl substituted with 0-1 R^{25}, and a phenyl substituted with 0-3 R^{15};

~~and with the proviso that R^3, R^5, R^6, R^7, and R^8 are not all hydrogen.~~

2-3. (canceled)

4. (previously presented) The compound of claim 1, wherein R^1 is phenyl substituted with 0-3 R^{1a}.

5-6. (canceled)

7. (previously presented) The compound of claim 9 wherein:

R^1 is C_3-C_8 cycloalkyl substituted with 0-2 R^{1b}, wherein said C_3-C_8 cycloalkyl is saturated or unsaturated; and

R^2 is a member selected from the group consisting of a phenyl substituted with 0-3 R^{15}, a C_1-C_6 alkyl substituted with 0-2 R^{2a}, and a C_3-C_7 cycloalkyl substituted with 0-2 R^{19}.

8. (previously presented) The compound of claim 9, wherein:

R^2 is a member selected from the group consisting of a C_1-C_2 alkyl substituted with 1 R^{2a}, and C_1-C_6 alkyl;

each R^{2a} is independently a member selected from the group consisting of a phenyl substituted with 0-3 R^{15}, and a C_3-C_8 cycloalkyl substituted with 0-2 R^{19};

R^5 is a member selected from the group consisting of H, C_3-C_7 cycloalkyl; and a C_1-C_6 alkyl substituted with 0-1 R^{18}; and

each R^{18} is independently a member selected from the group consisting of H, OH, F, Cl, CN, $C(=O)OR^{30}$, $C(=O)NR^{13}R^{14}$, $NR^{11}R^{12}$, a phenyl substituted with 0-3 R^{15}, and C_3-C_8 cycloalkyl.

9. (previously presented) The compound of claim 1, wherein said compound is of the formula:



10-15. (canceled)

16. (previously presented) The compound of claim 18 wherein:

R^1 is C_6-C_{10} aryl substituted with 0-3 R^{1a}; and

each R^{1a} is independently a member selected from the group consisting of H, C_1-C_3 perfluoroalkyl, C_3-C_7 cycloalkyl, F, Cl, Br, CN, NO_2, OR^{10}, SCH_3, $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{11}R^{12}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, phenyl substituted with 0-3 R^{15}, and a C_1-C_4 alkyl substituted with 0-2 R^{16}.

17. (previously presented) The compound of claim 18, wherein:

R^2 is a member selected from the group consisting of a C_1-C_2 alkyl substituted with 1 R^{2a}, and C_1-C_6 alkyl;

each R^{2a} is independently a member selected from the group consisting of a phenyl substituted with 0-3 R^{15}, and a C_3-C_8 cycloalkyl substituted with 0-2 R^{19}; and

R^5 is a member selected from the group consisting of H, C_3-C_7 cycloalkyl; and a C_1-C_6 alkyl.

18. (previously presented) The compound of claim 1, wherein said compound is of the formula:



19. (previously presented) The compound of claim 9 wherein:

R^1 is C_6-C_{10} aryl substituted with 0-3 R^{1a};

each R^{1a} is independently a member selected from the group consisting of H, C_1-C_3 perfluoroalkyl, C_3-C_7 cycloalkyl, F, Cl, Br, CN, NO_2, OR^{10}, SCH_3, $S(=O)CH_3$, $S(=O)_2R^{10}$, $NR^{11}R^{12}$, acetyl, $C(=O)OR^{13}$, $C(=O)NR^{13}R^{14}$, $S(=O)_2NR^{13}R^{14}$, phenyl substituted with 0-3 R^{15}; and a C_1-C_4 alkyl substituted with 0-2 R^{16};

R^2 is a member selected from the group consisting of a phenyl substituted with 0-3 R^{15}; a C_1-C_2 alkyl substituted with 1 R^{2a}, and a C_3-C_7 cycloalkyl substituted with 0-2 R^{19}; and

each R^{2a} is independently a member selected from the group consisting of a C_6-C_{10} aryl substituted with 0-3 R^{15}; a C_3-C_8 cycloalkyl substituted with 0-2 R^{19}; and a C_7-C_{11} bicycloalkyl substituted with 0-2 R^{19}.

20-26. (canceled)

27. (currently amended) A pharmaceutical composition comprising the compound of [[~~Formula I(i) or I(j) in claim 1~~]] claim 9 and a pharmaceutically acceptable excipient.

28. (previously presented) A pharmaceutical composition comprising the compound of claim 38 and a pharmaceutically acceptable excipient.

29-37. (canceled)

38. (currently amended) The compound of claim 1, selected from the group consisting of:

(S)-N-{1-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-phenoxy-benzamide;

(S)-3-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-[2-(4-methoxy-phenyl)-acetylamino]-propionamide;

(S)-N-{1-[2-(5-Chloro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(7-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(6-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(7-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-cyano-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

Cyclopropanecarboxylic acid (S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-amide;

(S)-N-{3-Cyclohexyl-1-[2-(4-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-methoxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S)-N-{3-Cyclohexyl-1-[2-(5-benzyloxy-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

~~N-{(1S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1,1-dimethyl-ethylcarbamoyl]-2-phenyl-ethyl}-3-methyl-benzamide;~~

N-{3-Cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

N-{3-Cyclohexyl-1-(R)-[(S)-2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S,S)-5-(5-Fluoro-2,3-dihydro-indol-1-yl)-4-[4-methyl-2-(3-methyl-benzoylamino)-pentanoylamino]-pentanoic acid benzyl ester;

(S,S)-5-(5-Fluoro-2,3-dihydro-indol-1-yl)-4-[4-methyl-2-(3-methyl-benzoylamino)-pentanoylamino]-pentanoic acid;

(S,S)-*N*-{1-[3-Carbamoyl-1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-propylcarbamoyl]-3-methyl-butyl}-3-methyl-benzamide;

(S,S)-3-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

(S,S)-3-[4-Cyclohexyl-2-(3-methoxy-benzoylamino)-butyrylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

(S,S)-N-{1-[1-Benzyl-2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-3-cyclohexyl-propyl}-3-methoxy-benzamide;

(S,S)-N-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-3-methyl-butylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S,S)-*N*-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-2-methyl-propylcarbamoyl]-propyl}-3-methoxy-benzamide;

(S,S)-*N*-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-phenyl-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(2-fluoro-biphenyl-4-yl)-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-p-tolyl-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-o-tolyl-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(4-fluoro-phenyl)-propionamide;

2-(4-Chloro-phenyl)-N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-propionamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(R)-phenyl-propionamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-(methanesulfonylamino-methyl)-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methanesulfonyl-benzamide;

N-(S)-{2-cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-4-methanesulfonylamino-benzamide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(4-hydroxy-phenyl)-propionamide;

4-Cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(S)-(2-(R)-phenyl-propionylamino)-butyramide;

N-{2-cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-2-(R)-phenyl-butyramide;

N-{2-Cyclohexyl-1-(S)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-ethyl}-3-methoxy-benzamide;

N-{1-(S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1-(R)-hydroxymethyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-(S)-[2-(S)-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid tert-butyl ester;

3-(S)-[3-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-propionylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid benzyl ester;

3-(S)-[3-Cyclohexyl-2-(S)-(3-methoxy-benzoylamino)-propionylamino]-4-(5-fluoro-2,3-dihydro-indol-1-yl)-butyric acid;

4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-(S)-[2-(S)-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid ethyl ester;

N-{1-(S)-[2-Cyano-1-(S)-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-ethylcarbamoyl]-3,3-dimethyl-butyl}-3-methoxy-benzamide;

N-{1-(S)-[5-Amino-1-(S)-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-pentylcarbamoyl]-3-cyclohexyl-propyl}-3-methoxy-benzamide;

(S,S)-N-{3-Cyclohexyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(4-hydroxy-benzyl)-ethylcarbamoyl]-propyl}-3-methoxy-benzamide;

Cyclopropanecarboxylic acid {1-(*S*)-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-(*S*)-methyl-ethylcarbamoyl]-3,3-dimethyl-butyl}-amide;

N-((S)-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)(cyclohexyl) methyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(2-chlorophenyl)ethyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(3-chlorophenyl)ethyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-(4-chlorophenyl)ethyl)-3-methylbenzamide;

(S)-N-{2-Cyclopentyl-1-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylcarbamoyl]-ethyl}-3-methyl-benzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-3,3-dimethylbutyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-3-cyclohexylpropyl)-3-methylbenzamide;

N-((S)-1-(2-(5-fluoroindolin-1-yl)ethylcarbamoyl)-2-phenylethyl)-3-methylbenzamide;

N-(R,S)-((3-(5-fluoroindolin-1-yl)-1-hydroxypropan-2-(R)-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;

(R,S)-N-((2-(5-fluoroindolin-1-yl)ethylcarbamoyl)(2,4-dichlorophenyl)methyl)-3-methylbenzamide;

(S,S)-N-((3-(5-fluoroindolin-1-yl)-1-hydroxypropan-2-ylcarbamoyl)(2,4-dichlorophenyl)methyl)-3,4-difluorobenzamide;

(S,S)-4-(5-Fluoro-2,3-dihydro-indol-1-yl)-3-[2-(3-methoxy-benzoylamino)-4,4-dimethyl-pentanoylamino]-butyric acid; and

(S,S)-N-{3-Cyclohexyl-1-[1-(5-fluoro-2,3-dihydro-indol-1-ylmethyl)-3-hydroxy-propylcarbamoyl]-propyl}-3-methoxy-benzamide.

39. (new) A pharmaceutical composition comprising the compound of claim 18, and a pharmaceutically acceptable excipient.

40. (new) N-{(1S)-[2-(5-Fluoro-2,3-dihydro-indol-1-yl)-1,1-dimethyl-ethylcarbamoyl]-2-phenyl-ethyl}-3-methyl-benzamide.

41. (new) The compound of claim 40, and a pharmaceutically acceptable excipient.